Nasus Pharma is trading at $3.00, down 6.25%, with no confirmed catalyst for the November 4 decline.
- No company-specific announcement explaining the November 4 decline surfaced in available news listings.
- Recent analyst coverage and price-target changes predate this session. The broader market and healthcare sector are rising, so they do not align with or explain the drop.
- The November 3 report also noted no specific announcement explaining that sessionβs move.